Copyright © Inderes 2011 - present. All rights reserved.

Revenio Group

18.10 EUR

-0.77 %

14,254 following
Corporate customer

REG1V

NASDAQ Helsinki

Medical Equipment & Services

Health Care

-0.77 %
-4.74 %
-19.20 %
-18.28 %
-22.65 %
-31.75 %
-51.11 %
-64.37 %
+852.63 %

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more
Market cap
482.93M EUR
Turnover
2.52M EUR
P/E (adj.) (26e)
20.42
EV/EBIT (adj.) (26e)
15.08
P/B (26e)
3.79
EV/S (26e)
3.74
Dividend yield-% (26e)
2.76 %
Coverage
Recommendation
Buy
Target price
24.00 EUR
Updated
12.02.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 12.02.2026

Latest extensive report

Released: 21.01.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
15.4
2026

General meeting '26

28.4
2026

Interim report Q1'26

6.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Revenio Q4'25 preview: Valuation reaches historic lows
Research by
Juha Kinnunen

Revenio Q4'25 preview: Valuation reaches historic lows

Revenio's valuation has fallen to a historically low level, as the industry faces concerns, especially after Zeiss's grim profit warning. We consider the concerns regarding Revenio to be exaggerated and estimate the company's earnings to be firmly on an upward trend this year.

Revenio Group
Revenio Q3'25: Q4 will decide this year too
Research by
Juha Kinnunen

Revenio Q3'25: Q4 will decide this year too

Revenio's Q3 earnings fell short of our overly optimistic expectations, but on the other hand, the Q4 outlook appears better than we anticipated. There have been no dramatic revisions in the outlook for the coming years, but the market is showing at least small signs of recovery.

Revenio Group
Forum discussions
This is a bit tricky to answer, as acquisitions can of course be financed in many ways. But if we ignore share issues and using their own shares for now, Revenio’s balance sheet could very conservatively withstand at least 2x EBITDA in pure debt. That would be around 60 MEUR, if ...
2/24/2026, 7:32 PM
by Juha Kinnunen
40
Four years ago, I was looking into OCT players and wrote here, when the share price was over EUR 40, that Optopol from Poland would be the best fit for Revenio’s product portfolio and could be acquired through a share swap. It is just over a third of Revenio’s size. Time has passed...
2/24/2026, 4:14 PM
by ZeroGravity
27
Yeah, my AI detector saw it in Jouni’s eyes in the interview that OCT will be in Reve’s portfolio within the current year : ) Juha’s extensive report stated just over a year ago: “In our view, the most obvious area for expanding Revenio’s device offering is Optical Coherence Tomography...
2/24/2026, 6:17 PM
by Von Wangell
23
Rumor has it that the OYS eye clinic has studied and found Revenio’s Thirona to be effective in screening for retinopathy, maculopathy, and apparently glaucoma as well. It was disappointing to hear that OCT was used in the studies with Thirona—well, obviously—but Revenio doesn’t ...
2/24/2026, 2:02 PM
by Optis
21
It would certainly be an excellent fit for Revenio. The company in question has an interesting story, as it was listed on the Warsaw Stock Exchange from 2008 to 2010, when Canon bought the company and delisted it. In 2014, the founding family bought the company back from Canon. Their...
2/24/2026, 4:22 PM
by MTES
18
A suitable mix of cash, stock, and debt would certainly enable even a larger acquisition. Revenio’s share price decline last year is a bit of a double-edged sword when using their own stock as currency. From the seller’s perspective, this is a good thing (if there’s a directed issue...
2/25/2026, 6:22 AM
by MTES
17
There has indeed been a lot of speculation about these corporate restructurings for a long time. While wondering and waiting, only Demant’s ownership of Revenio has increased. And the number of board members has also grown from five in 2024 to the current seven. By the way, the company...
2/23/2026, 2:47 PM
by Von Wangell
11
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.